Romuald Bellmann

Romuald Bellmann

Auto-generated profile, based on publicly available information

Romuald Bellmann

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2017 in Infection
Verified
Journal Article
Open access
PDF file
RBRomuald Bellmann
Romuald Bellmann
PSPiotr Smuszkiewicz
Piotr Smuszkiewicz
Introduction Because of the high mortality of invasive fungal infections (IFIs), appropriate exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials and methods This review summarises published pharmacokinetic data on systemically administered antifungals focusing on co-morbidities, target-site penetration, and combination antifungal therapy. Conclusions and discussion Amphotericin B is eliminated unchanged via urine and faeces. Flucytosine and fluconazole display low protein binding and are eliminated by the kidney. Itraconazole, voriconazole, posaconazole and isavuconazole are metabolised in the liver. Azoles are substrates and inhibitors of cytochrome P450 (CYP) isoenzymes and are therefore involved in numerous drug–drug interactions. Anidulafungin is spontaneously degraded in the plasma. Caspofungin and micafungin undergo enzymatic metabolism in the liver, which is independent of CYP. Although several drug–drug interactions occur during caspofungin and micafungin treatment, echinocandins display a lower potential for drug–drug interactions. Flucytosine and azoles penetrate into most of relevant tissues. Amphotericin B accumulates in the liver and in the spleen. Its concentrations in lung and kidney are intermediate and relatively low myocardium and brain. Tissue distribution of echinocandins is similar to that of amphotericin. Combination antifungal therapy is established for cryptococcosis but controversial in other IFIs such as invasive aspergillosis and mucormycosis.

1 October 1992 in Neuroscience
Verified
Journal Article
Closed access
GSG. Sperk
G. Sperk
JMJ. Marksteiner
J. Marksteiner
BGB. Gruber
B. Gruber
RBR. Bellmann
R. Bellmann
MMM. Mahata
M. Mahata
MOM. Ortler
M. Ortler

1 May 1990 in Neuroscience Letters
Verified
Journal Article
Closed access
JMJosef Marksteiner
Josef Marksteiner
MOMartin Ortler
Martin Ortler
RBRomuald Bellmann
Romuald Bellmann
GSGünther Sperk
Günther Sperk

4 April 2006 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
HVHelene Vogelsinger
Helene Vogelsinger
SWStefan Weiler
Stefan Weiler
ADAngela Djanani
Angela Djanani
JKJordan Kountchev
Jordan Kountchev
RBRosa Bellmann-Weiler
Rosa Bellmann-Weiler
RBRomuald Bellmann
Romuald Bellmann
Objectives: Tissue concentrations of amphotericin B were determined in autopsy material of patients who had been treated with liposomal amphotericin B or amphotericin B colloidal dispersion (colloidal amphotericin B) for suspected or proven invasive fungal infection. Patients and methods: Amphotericin B tissue levels were measured in liver, spleen, lung, kidney, and myocardial and brain tissue of 20 patients who had been treated with lipid-formulated amphotericin B, before they died from multi-organ failure. Seven patients had been treated with liposomal amphotericin B (AmBisome®) and thirteen with colloidal amphotericin B (Amphocil®). Tissue samples were obtained during routine autopsy, homogenized and extracted with methanol. Amphotericin B concentrations were measured using HPLC after purification by solid phase extraction. Results: The highest amphotericin B levels were found in liver and spleen, followed by kidney, lung, myocardium and brain. In the lung higher amphotericin B concentrations were found after treatment with amphotericin B colloidal dispersion than after therapy with liposomal amphotericin B. Conclusions: The choice of lipid formulation may influence amphotericin B penetration into the lung.

1 February 1991 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
RBRomuald Bellmann
Romuald Bellmann
RWRudolf Widmann
Rudolf Widmann
COClaudia Olenik
Claudia Olenik
DMDieter K. Meyer
Dieter K. Meyer
DMDagmar Maas
Dagmar Maas
GSGünther Sperk
Günther Sperk

15 April 1997 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PSP Schratzberger
P Schratzberger
NRN Reinisch
N Reinisch
WPW M Prodinger
W M Prodinger
CKC M Kähler
C M Kähler
BSB A Sitte
B A Sitte
CWC J Wiedermann
C J Wiedermann
We studied the chemotactic effects of calcitonin gene-related peptide, vasoactive intestinal peptide, substance P (SP), and secretoneurin on PBMC and PBL using micropore filter assays. All four peptides induced migration of PBMC, whereas only calcitonin gene-related peptide, vasoactive intestinal peptide, and SP were chemotactic for PBL. Secretoneurin, known to induce monocyte chemotaxis, was unable to affect lymphocyte migration. Effects of SP on PBL were characterized by checkerboard analyses and represented true chemotaxis. Both T and B cells responded chemotactically to SP, the functional activity of SP residing in its C-terminal amino acid sequence. Involvement of neurokinin (NK) receptors was supported by inhibition of SP-induced migration of PBL with an NK1 receptor antagonist and induction of migration with [Sar9, Met(O2)11]SP and [PyrGlu6, Pro9]SP(6-11), two specific agonists for NK1 receptors, but not with [beta-Ala8]NK A(4-10), an agonist for NK2 receptors. PBL chemotaxis to SP was abolished by inhibition of tyrosin kinase but not by that of protein kinase C. Preincubation of PBL with pertussis or cholera toxin inhibited SP chemotaxis, indicating that in PBL, NK receptors for chemotaxis probably are coupled with G protein and involve a tyrosin kinase signaling pathway. We conclude that, together with calcitonin gene-related peptide and vasoactive intestinal peptide, SP is a lymphocyte chemoattractant, whereas secretoneurin, which is coreleased from sensory nerve endings, is not.